10 Jun

How Analysts Rate Tandem Diabetes Care and Insulet

WRITTEN BY Margaret Patrick

Evolving insulin delivery landscape

Until the start of 2017, the insulin pump technology space was mainly dominated by big companies such as Medtronic (MDT) and Johnson & Johnson (JNJ). However, in October 2017, Johnson & Johnson issued a press release announcing intentions to exit the insulin pump market. The company also offered to transfer around 90,000 of its patients using Animas insulin pumps to Medtronic’s pump.

Although Medtronic was the major beneficiary of Johnson & Johnson’s exit, this event coupled with a continuous focus on innovation has driven uptake of insulin pumps offered by smaller diabetes MedTech players such as Tandem Diabetes Care (TNDM) and Insulet (PODD).

Tandem Diabetes Care rallied by 1,394.88% in 2018 from $2.54 on January 2 to $37.97 on December 31. The stock has been already up by 88.83% in 2019 YTD and closed at $71.70 on June 7. Insulet Corp rose by a lower 14.96% from $69.00 on January 2 to $79.32 on December 31. However, the stock is also 40.46% up in 2019 YTD and closed at $111.41 on June 7. To evaluate which of the two is a better pick in the long run, we take a look at the various pros and cons of both the companies.

Analysts’ recommendations and Target price

The consensus recommendation for both Tandem Diabetes Care and Insulet Corp is “buy.” Wall Street analysts expect an upside potential of 11.58% for Tandem Diabetes Care based on the company’s closing price on June 7. Analysts have gradually increased the company’s 12-month consensus target price from $67.27 in February to $72.00 in March to $78.92 in April to $80.00 in May. The highest and lowest target estimate is 100 and 70, respectively. Out of 13 analysts covering Tandem Diabetes Care, four recommend a “strong buy,” six recommend a “buy,” and three recommend a “hold.”

Wall Street analysts expect a downside potential of 4.07% for Insulet Corp based on the company’s closing price on June 7. Analysts have gradually increased the company’s 12-month consensus target price from $103.73 in February to $104.40 in March to $106.56 in April to $106.88 in May. The highest and lowest target estimate is 118 and 97, respectively.

Out of 18 analysts covering Insulet, seven recommend a “strong buy,” seven recommend a “buy,” and four recommend a “hold.”

Latest articles

Investors have been holding their breath for a Fed rate cut for a while now. But are they prepared in the event that that doesn't happen?

Innovative Industrial Properties (IIPR) continued to slump on July 22. The stock lost almost 6.8% of its value on the day.

22 Jul

Why AT&T Stock Is Down 2.2% Today

WRITTEN BY Ambrish Shah

AT&T stock (T) was trading at $32.14 with a 2.0% loss for the day. Earlier today, it posted a low of $32.08. Is the stock overvalued right now?

The Walt Disney Company’s (DIS) superhero film Avengers: Endgame has finally surpassed the record set by James Cameron’s Avatar.

22 Jul

Why Durect Corporation Is Soaring Today

WRITTEN BY Margaret Patrick

On July 22, Durect Corporation (DRRX) entered into a collaboration with HIV leader Gilead Sciences (GILD).

Pure Alpha, the flagship fund of Ray Dalio’s Bridgewater Associates, fell 4.9% in the first half, the Financial Times reported.